Jane Griffiths, global head of Actelion – acquired in 2017 by Johnson & Johnson – discusses her priorities heading up an iconic rare disease-focused biotech and gives her take on a wide range of hot-button industry issues; from the future of M&As to patient-centricity, women in leadership and digital disruption.
Yes, we are integrating a business, but, at the end of the day, our focus is, and will continue to be, enhancing and optimizing treatment pathways and delivering improved options for patients
